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Abstract
Background—Studies testing the efficacy of behavioral interventions to modify psychosocial 
sequelae of IBD in children are limited. This report presents outcomes through a six month follow 
up from a large RCT testing the efficacy of a cognitive-behavioral intervention for children with 
IBD and their parents.
Methods—185 children age 8-17 years with a diagnosis of Crohn's (CD) or Ulcerative Colitis 
(UC) and their parents were randomized to one of two 3-session conditions: 1.) a social learning 
and cognitive-behavioral therapy condition (SLCBT) or 2.) an education support condition 
designed to control for time and attention.
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Results—There was a significant overall treatment effect for school absences due to CD or UC 
(p<.05) at 6 months post-treatment. There was also a significant overall effect post-treatment for 
child-reported quality of life (p<.05), parent- reported increases in adaptive child coping (p<.001) 
and reductions in parents’ maladaptive responses to children's symptoms (p<.05). Finally, 
exploratory analyses indicated that for children with a higher level of flares (2 or more) pre-
baseline, those in SLCBT experienced a greater reduction in flares post-treatment.
Conclusions—This trial suggests that a brief cognitive-behavioral intervention for children with 
IBD and their parents can result in improved child functioning and quality of life, and for some 
children may decrease disease activity.
Keywords
Inflammatory Bowel Disease; Crohn's Disease; Ulcerative Colitis; Pediatric Gastroenterology; 
Quality of Life
INTRODUCTION
Inflammatory Bowel Disease (IBD) is a serious medical condition that has broad adverse 
health implications and is being seen with increasing frequency among children.1-3 IBD 
usually refers to two disorders: Crohn's disease (CD) and ulcerative colitis (UC). Both 
conditions are diagnosed after positive medical findings have determined chronic 
inflammation in the gastrointestinal tract. IBD can lead to increased rates of missed school 
or work, medical costs, hospitalizations, surgery, and even death.4,5 Although IBD is not 
believed to have a psychosocial origin, a number of studies have identified psychosocial 
variables associated with the disease,6-8 some of which clearly have the potential for 
significantly affecting the quality of life of IBD patients.9-11 Comparing children with IBD 
to matched controls, researchers have found more anxiety, depression, social functioning 
(inter-personal interactions in social situations) problems and family dysfunction in those 
with IBD.7 Many studies have found depression in particular is increased in youth with IBD 
compared to controls7 and parents of children with IBD also show increased levels of 
depression.12
Considerable research has found an association between psychosocial factors, most notably 
anxiety and/or depression as well as maladaptive coping, and IBD symptoms and symptom 
severity in children with IBD.7,13-17 Typical of these, recently Reigada et al.18 found that 
anxiety symptoms were significantly associated with moderate/severe disease activity 
among children and adolescents with CD. Similarly, Srinath et al.19 found that depression 
was a significant predictor of abdominal pain in children and adolescents with IBD, perhaps 
more so in UC than in CD. Reed-Knight et al20 also found that higher ratings of disease 
severity were related to greater depressive symptoms in youth with IBD. Finally, how 
children cope with IBD has also been found to be associated with physical symptoms, 
quality of life and disability.14 Catastrophizing (the tendency to describe an experience or 
the likely outcome of the experience in exaggerated negative terms) in particular has been 
found to be associated with negative outcomes such as disability and depression in youth 
with IBD.21,22
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Studies testing the efficacy of interventions to modify these psychosocial factors have been 
limited. In one small trial (n=22), cognitive behavioral therapy (CBT) was shown to reduce 
depression in youth with IBD; the CBT group was compared to treatment as usual,23 rather 
than a condition that controlled for time and attention. Content for this intervention was 
delivered on nine modules during 9 to 11 sixty-minute sessions. A 2014 study by the same 
group included 178 depressed youth age 9-17 with active IBD who received 3 months of 
either CBT (teaching coping skills) or supportive nondirective therapy (SNDT; empathic 
listening and reflecting by the therapist in response to content raised by the patient).24 The 
intervention was a 12-session intervention spanning three months. Results showed 
significantly greater reduction in disease activity for the CBT group vs. the SNDT group. 
Although there were significant reductions in depressive symptoms overall, group 
differences were not significant. A secondary analysis of these data with a subsample of 
adolescents with CD found significantly greater reductions in both depressive symptoms and 
disease activity for the CBT group vs. the SNDT group after excluding those taking 
steroids.25 However, there were some limitations of these studies, most notably the inclusion 
of only depressed participants and the absence of any follow-up period, as outcome data 
were only obtained immediately following treatment. Additionally, these interventions, 
while consistent with traditional CBT approaches for depression which are typically 8-15 
sessions long, may not be practical in many clinical settings, or necessarily applicable to 
interventions aimed at coping with health problems such as IBD.
The present randomized controlled study tested the efficacy of a brief CBT intervention on 
reducing the negative impact of IBD on children's lives. The intervention was designed as an 
adaptation for IBD of a three session cognitive behavioral intervention that was previously 
shown to be effective in reducing symptoms and disability in children with unexplained 
abdominal pain.26,27 This prior study targeted reductions in parent solicitousness and 
increases in children's adaptive pain coping efficacy beliefs and use of adaptive coping 
strategies. The current study focused on the same targets, but modified the intervention 
content to include coping with IBD as well as parent and child responses specifically to IBD 
symptoms, rather than idiopathic abdominal pain. Thus, in the present study we sought to 
demonstrate reductions in parent solicitousness and increases in children's adaptive pain 
coping efficacy beliefs and use of adaptive coping strategies for families receiving the CBT 
intervention, relative to a comparison condition. We also predicted that, as a result of 
training in children and parents in coping and adaptive responses to illness, children in the 
CBT group would be less likely to miss school or other activities due to illness-related 
concerns, thus showing greater improvements in quality of life, and reductions in disability, 
health care utilization and school absenteeism. Although our intervention was not 
specifically designed to reduce anxiety or depression, we included depression and anxiety as 
secondary outcome variables given the association between cognitive factors and anxiety/
depression symptoms. Addressing the methodological limitations of prior CBT studies in 
IBD, the current intervention was aimed at children and their parents and included follow-up 
assessments through one year post intervention.
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MATERIALS AND METHODS
Study Design
The study design was prospective, randomized, and longitudinal. The treatment and 
comparison conditions each included three sessions that were approximately one week apart 
(mean = 9.36 days, SD = 4.54). The study was approved by the institutional review boards at 
each site. The study was registered with ClinicalTrials.gov as study number NCT00679003.
Participants
Participants included 185 children, age 8–17 years, with a diagnosis of Crohn's or Ulcerative 
Colitis (UC) at least three months post-diagnosis, and their parents. Pediatric 
gastroenterology collaborators recommended the three month time since diagnosis to allow 
for initial medical treatment adjustment. Families were recruited over a 4 1/2-year period 
from 2008–2012 through physician referral from the pediatric GI clinics at Seattle Children's 
Hospital and Mary Bridge Children's Hospital in Tacoma WA. All interested participants 
were screened for eligibility by the physician co-investigator in the respective GI clinic. 
Parents gave informed consent, and children gave assent before commencement of research 
procedures.
Inclusion criteria were as follows: (i) child age 8–17 years, (ii) child received a diagnosis of 
Crohn's or UC and was at least three months post-diagnosis, (iii) child lived with the 
participating parent or caregiver for at least the last 3 months, (iv) child and parent were 
willing and able to complete the questionnaires and agreed to participate in the intervention 
and follow-up evaluations, and (v) child was medically approved to engage in normal 
activities (e.g., attend school, extracurricular activities). Exclusion criteria were as follows: 
(i) a chronic disease other than IBD (e.g., pancreatitis, diabetes, epilepsy), (ii) major surgery 
within the past year unrelated to IBD, (iii) developmental disabilities requiring full-time 
special education or impairing ability to communicate, and (vi) non-English speaking.
Randomization and assignment
Participants were enrolled by a researcher at the recruitment site prior to baseline assessment 
and randomization. Randomization was then performed by a different researcher using a 
computerized random-number generator, stratifying by age (7-11 or 12-18 years old) and 
then by physician-reported disease severity (quiescent, mild, or moderate/severe based on 
either the Pediatric Ulcerative Colitis Activity Index-PUCAI for UC patients or the Pediatric 
Crohn's Disease Activity Index-PCDAI for Crohn's patients) completed during enrollment. 
Randomization did not occur until baseline assessments for both children and parents were 
completed. Participants were blind to their group assignment, and were told that they would 
be randomly assigned to one of two treatment groups, and that the topics they would discuss 
would vary depending on the group to which they were assigned. They were not informed 
which condition was the treatment versus control condition.
Condition structure
Participants in both conditions continued with their regular medical care as recommended by 
their health-care team. Following baseline assessment and randomization, all participants 
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met with a trained therapist (Master's degree or higher) for three sessions spaced 
approximately 1 week apart (mean time spread from session 1 to session 3 = 18.6 days, SD 
= 6.6). Study therapists were trained in and administered both interventions. Participant 
families in both conditions had the choice of having these sessions either in the hospital 
clinic (35.7% of the sample) or, for convenience, their homes (64.3%).The mean session 
length was 70.68 minutes (SD = 14.31). In both treatment conditions, parents and children 
participated in the sessions together. At the end of the session, the therapist met separately 
with the child (5 minutes) and the parent (5 minutes) to discuss any topics they might have 
felt uncomfortable discussing in each other's presence, reiterate the importance of data 
collection and completing homework assignments, and role playing as time allowed. The 
participating parent was encouraged to share what was discussed as well as the handouts 
with the non-participating parent. Between sessions, parents and children in both conditions 
were asked to complete homework assignments related to the content of his/her respective 
treatment condition. A total of 89.5% of SLCBT participants and 87.1% of ES participants 
completed between-session homework packets.
Experimental Conditions
Social learning and cognitive-behavioral therapy conditions (SLCBT)—The 
SLCBT treatment condition is a form of CBT based on two principles derived from previous 
research: (i) consistent with social learning theory28 parents who respond solicitously to the 
child's illness reports and parents who report GI symptoms themselves (i.e., who may model 
illness behavior) tend to have children with more GI symptoms,29 and (ii) beliefs about the 
significance of symptoms, perceptions of one's pain coping efficacy, and the type of coping 
strategies used to manage them may influence symptom and disability reports.30-34 Over the 
course of three sessions, parents and children were taught to think about and cope with 
symptoms in ways that encouraged wellness, rather than illness behavior. Specifically, for 
both parents and children, this included instruction in cognitive-behavioral coping strategies 
of relaxation, stress management, and cognitive techniques (e.g., examining and altering 
self-talk). Cognitive strategies presented and practiced included identifying and changing 
maladaptive cognitions such as catastrophizing. Parents also received training to 
differentially attend to and reinforce wellness behaviors, rather than respond solicitously to 
illness behaviors, which could potentially reinforce them. Active skill practice in-session and 
identification and assignment of skills learned during the session to practice between 
sessions occurred throughout the intervention phase.
Education Support Comparison Condition (ES)—The use of an education-based 
control group is a standard control comparison in trials of CBT.35,36 Our ES condition 
consisted of educational content focused on the gastrointestinal system, food labels, and 
nutrition. The ES condition controlled for therapist and patient time and attention and was 
designed to provide a credible comparison condition without including content specific to 
the SLCBT intervention as outlined above. Parents and children in the ES condition met 
with the therapist for three sessions approximately equal in timing to the SLCBT condition. 
Therapists were instructed to not endorse any specific food or diet recommendations.
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Condition comparability and treatment fidelity—To assess the comparability of the 
treatment arms on measures of treatment participation, we measured the number of sessions 
completed by participants. 93.4% and 89.4% of participants completed the three sessions of 
the SLCBT and ES interventions, respectively (p = .45). To assess comparability of 
participant expectations about the two conditions, both parents and children were asked to 
rate their beliefs about the intervention with questions about how logical this type of therapy 
seemed. This scale was then mailed back to the study office in a sealed stamped envelope 
and thus not seen by the therapist. There were no significant differences between groups on 
participant ratings of the credibility of the intervention (p = .42).
Fidelity to the protocols associated with each condition was assessed by experienced 
intervention trainers who listened to audiotapes of at least one session for 23% of the cases 
who completed treatment. These sessions were scored to determine whether the therapist 
had included the appropriate elements for that treatment condition. Sessions were sampled 
from each therapist, and were selected within therapists on a random basis. Treatment 
fidelity was assessed on 38 cases (102 separate sessions) and was found to be at 96.86% of 
elements included on average for SLCBT, and 100% for ES (NS).
Data Collection Procedures
Assessment data were collected at baseline (T1), 1 week post-treatment (T2) and at follow-
up evaluations conducted three, six, and 12 months post-treatment (T3-5). Physicians 
completed disease severity measures at baseline and during enrollment. At all assessment 
points, parents completed questionnaires online or by mail (whichever modality they 
preferred). Children completed assessments through a scheduled telephone call with a highly 
trained research nurse who was blinded to the participant's treatment assignment. 
Appointments for assessments were scheduled in advance, and answer keys were mailed to 
children before the calls. Answer keys guided children through the questions and response 
options, aiding administration.
Measures
Child and parent demographics and child medical history were completed by parents.
Process Variables
Parent Report only: Parental response to pain behavior was measured using the 13-item 
Protect subscale of the Adults’ Responses to Children's Symptoms (ARCS).37,38 Sample 
items of this measure which asses constructs such as parent reinforcement of illness 
behavior include, “When your child has a stomachache or other GI symptoms, how often do 
you bring him/her special treats or little gifts?” or “...let him/her stay home from school?” 
Ratings are made on a 0–4 scale, with higher values indicative of greater solicitousness. 
Parents completed the items with respect to themselves.
Parent and Child Report: Child catastrophizing and pain coping skills were measured 
using the Pain Response Inventory (PRI).39,40 The Pain Response Inventory assesses child 
responses to pain. For the present study the item stems were slightly modified to include 
other GI symptoms as well (i.e., “when you have a stomachache or other stomach problems, 
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how often do you...” for child report and “when your child has a stomachache or other GI 
problems, how often does he/she...” for parent report). This inventory includes multiple 
subscales, but the ones targeted by the SLCBT intervention and analyzed in this study were 
the Catastrophizing and Distract/Ignore scales. The catastrophizing subscale contains 5 
items such as, “When you have a stomachache or other stomach problems, how often do you 
think to yourself that you might be really sick?” This Distract/Ignore subscale contains 5 
items such as, “When you have a stomachache or other stomach problems, how often do you 
do something you enjoy so you won't think about it?” Items are rated on a 0–4 scale, with 
higher values indicative of greater catastrophizing or greater distract/ignore responses. 
Parents completed the items with respect to their child and children completed the items 
with respect to themselves.
Pain beliefs and coping were assessed using the Pain Beliefs Questionnaire (PBQ).39,41 The 
Pain Threat subscale with 20 items assesses the perceived duration, frequency, and 
seriousness of the abdominal pain condition, as well as the intensity and duration of 
individual pain episodes. For the present study, to more broadly assess the impact of IBD 
symptoms, we slightly modified items to refer to IBD symptoms (parent questionnaire- i.e., 
“my child's IBD symptoms hurt a whole lot”) or stomach problems (child questionnaire- i.e., 
“I get stomach problems all the time”) instead of stomach aches (as noted in the original 
questionnaire). Two additional subscales assess Emotion-focused Coping Efficacy (items 
such as, “I know I can handle it no matter how bad my stomach problems are”) and 
Problem-focused Coping Efficacy (6 items such as, “When I have bad stomach problems, I 
can find ways to feel better”). Items are rated on a 0-4 scale with higher values indicative of 
greater pain threat. Children completed the items with respect to themselves, and parents 
completed the items with respect to their child.
Outcome Variables
Parent report only: Health care utilization was assessed by asking parents to 
retrospectively report the number of hospital stays and the number of visits to a health care 
provider (medical doctor/nurse practitioner/physician assistant) their child had for Crohn's or 
UC. The time frame for these reports were the prior 12 months at baseline, the prior three 
months at the 3- and 6-month assessments, and in the prior 6 months at 1 year follow up.
School attendance was measured by asking the parent to report on the number of days the 
child missed school (or other activities such as camp or sports when school was not in 
session) because of stomachaches or other GI symptoms. The time frames for these reports 
were the previous 3 months at baseline, 3- and 6-month assessments, and the previous 6 
months at 1 year follow up.
Child report only: IBD-specific quality of life (QOL) was assessed using the IMPACT-
III,42 a self-report measure that includes 35 items across six domains: Bowel Symptoms (7 
items), Systemic Symptoms (3 items), Social Functioning (12 items), Body Image (3 items), 
Treatment/Interventions (3 items), and Emotional Functioning (7 items). We utilized a 
slightly modified version of 33 items suggested by Otley et al.42 and Perrin et al.43 Items are 
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scored on a 5-point Likert Scale. For the purposes of this study we only utilized the total 
score, which can range from 33 to 175, with higher scores indicating better QOL.
Children's depressive symptoms were measured using the Child Depression Inventory 
(CDI).44,45 The CDI is a valid and reliable self-report measure of children's depressive 
symptoms.46 It contains 27 self-report items representing depressive symptoms that are rated 
on a 3-point scale, although we omitted the single item designed to assess suicidal ideation 
given that depression was not the focus of the study and we were concerned about 
administering this question to young children using a telephone format. Higher scores 
indicate greater depressive symptoms. Total scores are computed by taking the sum of the 
items.
Children's anxiety was measured using the Multidimensional Anxiety Scale for Children 
(MASC)47 which provides a reliable and valid assessment of anxiety symptoms across 
clinically important symptom domains including social anxiety, harm avoidance, separation/
panic, and physical symptoms. The MASC is a 39-item self-report measure which yields the 
aforementioned subscale scores, a total anxiety score and an anxiety disorders index. The 
present study utilized the latter, which has a sensitivity of 83%, a specificity of 92%, an 
overall correct classification rate of 88%, and a kappa was .75. Higher scores indicate 
greater anxiety. Total scores are computed by taking the sum of the items.
Parent and child report: General activity limitations were measured using the Functional 
Disability Inventory (FDI).48 The FDI assesses difficulty in physical and psychosocial 
functioning as it relates to a child's physical health. The scale contains 15 items rated on a 
0-4 scale that ask about difficulty doing regular activities (e.g., walking up stairs, doing 
chores, watching television). A total score is derived by summing responses to all items. 
Higher scores indicate greater disability. Children completed the items with respect to 
themselves, and parents completed the items with respect to their child.
Disease information
Physician Report: Crohn's-disease activity was assessed at baseline using the Pediatric 
Crohn's Disease Activity Index (PCDAI).49 The PCDAI has been well documented as a 
valid, reliable, and feasible instrument to measure disease activity in children with Crohn's 
disease.50 Physicians document abdominal pain severity, stool frequency and consistency, 
and general patient functioning using a 1 week recall period. The most recent laboratory 
values for hematocrit (HCT %), erythrocyte sedimentation rate (ESR mm/hr), and albumin 
(g/dL) are also noted, as well as examination findings (including recent weight gain/loss, 
height, abdominal tenderness, perirectal disease, and extra-intestinal manifestations). Scores 
can range from 0 to 100, with higher scores indicating more disease activity. Compared to 
the adult version of the Crohn's Disease Activity Index, the PCDAI is better able to 
distinguish among quiescent (score of 0-10), mild (score of 12.5-30), and moderate/severe 
(score ≥30) levels of disease activity.51 It has also been found to be sensitive to short-term 
change.52
UC-disease activity was also assessed at baseline using the Pediatric Ulcerative Colitis 
Activity Index (PUCAI).53 The PUCAI has been shown to be valid, reliable, and responsive 
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in the assessment of UC disease activity. Scores can range from 0-85, with scores < 10 
indicative of remission (quiescent), 10-34 indicating mild disease, 35-64 indicating moderate 
disease, and 65-85 indicating severe disease.
Flare counts were collected on a subset of patients for which the data were available 
retrospectively at baseline (for the 12 months pre-consent) and then prospectively for the 15 
months post-treatment by checking medical records for an indication of a flare. Flares were 
determined either by physician records specifically stating the occurrence of a flare and/or, 
for Crohn's patients, a PCDAI score of 11+, and for UC patients a PUCAI score of 10+.
IBD-specific medical information was collected using a physician measure that included 
items from the Paris Classification,54 an evidence-based consensus classification system for 
pediatric IBD which defines IBD phenotypes. Data were collected at baseline on disease 
location (rectal [proctitis], left-sided colitis, or entire colon [pan colitis] for subjects with UC 
and small intestine only [ileitis], small and large intestine [ileocolitis] or large intestine only 
[colitis] for subjects with CD), the presence of other medical problems (anal, rectal, or 
vaginal problems such as fissure, fistula, or abscesses), and also indicated if the child was 
taking daily steroid or pain medications.
Data analysis
Linear mixed-effects regression models were used to compare treatment conditions on the 
change from baseline for outcome and process measures, adjusting for the two factors used 
to stratify the treatment randomization (child age and disease severity), and also adjusting 
for child gender, disease condition (UC or CD), study site, assessment time point (1 week, 3, 
6 or 12 months post-treatment) and baseline level of the dependent variable. Linear mixed-
effects models allow for specification of a covariance structure that accounts for the within-
subject correlation over time.55 Separate models were estimated for each measure and all 
models included an interaction between time and treatment condition to estimate the change 
from baseline for each assessment time and treatment condition. An omnibus test for all 
post-treatment assessment periods (df = 3) was performed to evaluate an overall effect of the 
intervention (SLCBT vs. ES), followed by separate significance tests for each post-treatment 
period. In addition, separate omnibus tests by treatment condition were performed to 
evaluate overall change from baseline for each treatment condition for all post-treatment 
periods (df = 3), followed by separate significance tests for each post-treatment period. 
Bonferroni-Holm post-hoc tests were used to account for multiple comparisons due to the 
three post-treatments assessments. In addition, 95% confidence intervals are reported for the 
change from baseline and difference between treatments, and Cohen's d is reported as a 
measure of the effect size based on the 12-month post-treatment.
Multiple imputation procedures were used to account for missing assessments, and to derive 
intervention effect estimates consistent with the intention-to-treat (ITT) principle, where all 
randomized subjects were included in the analyses including those who did not complete 
treatment. Baseline and follow-up values of the outcome or process measures, and the other 
covariates included in each model were used in the imputation of the missing values. A set 
of 10 multiple imputed datasets was generated using Markov chain Monte Carlo estimation, 
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and the results carried out for each dataset were combined using Rubin's rules to adjust the 
standard errors for the uncertainty about imputed values.56,57
Due to the skewed distributions for the number of health care visits and missed school days, 
additional analyses using log-linear regression models were conducted to compare these 
count outcomes over time. Generalized estimating equations (GEE) were used to fit the log-
linear models with robust standard error estimates that take into account the within-subject 
correlation over time.58 Similar to Poisson regression for count data, the log-linear model is 
used to estimate adjusted rate ratios (time frame in this analysis used a log link function to 
model the mean number of health care visits and missed school days as a function of 
treatment condition and time). A Poisson marginal variance was used in the fitting 
procedure, but the GEE method does not require the distribution of the outcomes to have a 
particular parametric form (e.g., a Poisson distribution). An omnibus test for all post-
treatment assessment periods (df = 3) was performed to evaluate an overall effect of the 
intervention (SCLBT vs. ES), followed by separate significance tests for each post-treatment 
period. Statistical analyses were conducted using SAS statistical software, version 9.3 (SAS 
Institute, Inc.).
Power
A sample size of 65 participants per condition was determined to have 80% power to detect 
differences as small as those observed in health care utilization, parental response (ARCS), 
and pediatric quality of life in our prior study of SLCBT in children with functional 
abdominal pain at a two-sided 0.05 significance level. To account for attrition and larger 
variability in IBD than functional abdominal pain patients at least 90 participants were 
recruited per condition.
ETHICAL CONSIDERATIONS
The study was conducted with the approval of institutional review boards at each site and in 
accordance with the ethical principles outlined in the Declaration of Helsinki. All 
participants provided informed consent (parents) and assent (children) at the time of 
enrollment.
RESULTS
Figure 1 illustrates the disposition of all participants at all stages of the study. 91 participants 
were randomly assigned to the SLCBT condition and 94 were assigned to the ES condition 
with over 89% completing all three treatment sessions and one or more follow-ups. Session 
and follow-up completion rates did not differ by treatment condition, p = .45 and p = .85, 
respectively.
Sample Characteristics
See Table 1 for complete baseline characteristics of the total sample and the samples for 
each condition. 90.3% of the participating parents and 47.0% of the children were female. 
The mean ages were 44.4 (SD=6.9) years for parents and 13.5 (SD=2.7) for children. 87.1% 
of the parents and 77.9% of the children identified as Caucasian. 68.6% of the sample had a 
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diagnosis of Crohn's Disease (CD). 63.0% of all patients’ disease severity was categorized as 
quiescent, 28.8% mild, and 8.2% moderate to severe. Parent-report and self-report ratings of 
pain severity were not included in our analyses due to low baseline pain severity scores in 
our sample. Parents in the ES condition reported their child had more health care visits in the 
prior 12 months to baseline for CD or UC (7.1 SLCBT vs 11.5 ES, p = .01; Table 2), but all 
other comparisons between groups revealed no significant differences in sample 
characteristics at baseline (Table 1). There were also no significant differences in any parent 
or child-reported measures for either condition based on whether the treatment sessions were 
delivered at home or in a clinic setting. As medication usage for steroids and pain 
medications was captured only at baseline, and other medications were reported at baseline 
as being used by a very small number of participants, we did not conduct any further 
analyses using these data.
Process Variables
There was a significant overall treatment effect for several of the process variables, as 
reported by parents and children, with parents and children in the SLCBT condition showing 
greater improvement, as predicted, than those in the ES condition (Table 3). Consistent with 
our prior studies26,27, parents in the SLCBT condition reported significantly greater 
reductions in solicitousness compared to parents in the ES condition overall (p = .02), and 
maintained a small to moderate treatment effect size at 12 months post-treatment compared 
to the ES condition. Parents in the SLCBT condition reported a significant increase in child 
coping by distraction/ignoring over time (p = .001), with the largest increase observed 1-
week after treatment. Parents in the SLCBT condition also reported significant increases in 
child problem-focused coping over time. In contrast, parents in the ES condition reported 
little change over time in child use of distraction/ignoring and child problem-focused 
coping. The results also indicated significantly greater reduction in parent-reported child 
catastrophizing one week after treatment in the SCLBT condition as compared to the ES 
condition.
Children in the SLCBT condition reported a significant decrease in catastrophizing over 
time (p = .01), whereas children in the ES condition had little evidence of change over time 
(p = .64). Similar to the parents, children in the SLCBT condition reported a significant 
increase in their use of distraction/ignoring over time (p = .03), whereas children in the ES 
condition did not (p = .49). Children in the both conditions reported an increase in problem-
focused coping over time.
Outcome Variables
Results for the outcome variables are reported in Tables 4-5. There was a significant overall 
treatment effect for child-reported IBD-specific quality of life (Table 4; p = .04) and parent-
reported number of missed school days due to Crohn's disease or ulcerative colitis (Table 5; 
p = .02). Children in both conditions reported improved IBD-specific quality of life over 
time, but children in the SLCBT condition reported significantly greater improvement by 1-
week post treatment (Table 4). Children in both conditions also reported less depression over 
time. Parents in the SLCBT condition reported fewer health care visits and missed school 
days for Crohn's disease or ulcerative colitis at 6 and 12 months post-treatment, but the 
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treatment difference was statistically significant (p < .05) only at 6 months post-treatment 
for the number of missed school days (Table 5). The number of hospital stays post-treatment 
was not compared between the conditions, because only 15 of the children had a hospital 
stay post-treatment. There was improvement over time for several other outcome variables, 
but the improvement was similar between the two conditions.
Data on flare counts were available for 56 children in the SLCBT condition and 60 in the ES 
condition. The average number of months of assessment for flares prior to baseline was 
similar between the SLCBT and ES conditions (mean (SD) = 14.0 (1.3) versus 14.0 (1.3) 
months; p = .89), as well as post-treatment (mean (SD) = 14.3 (1.3) versus 14.1 (1.1) 
months; p = .56). The mean (range) number of flares prior to baseline was 1.2 (0 to 6) in the 
SLCBT condition and 1.2 (0 to 8) in the ES condition. Post-treatment, the mean (range) 
number of flares was 0.6 (0 to 4) for the SLCBT condition and 0.9 (0 to 9) for the ES 
condition. Log-linear regression was used to compare the number of flares post-treatment 
between the two conditions, adjusting for the same variables used to compare the two 
conditions on the outcome and process variables, as well as adjusting for the number of 
flares prior to baseline. While there were fewer flares overall post-treatment in the SLCBT 
condition as compared to the ES condition, the difference was not statistically significant 
(rate ratio = 0.83; 95% CI, 0.41 to 1.32; p = .42). However, in an exploratory subgroup 
analysis, we observed that among children who had two or more flares prior to baseline (18 
in the SCLT condition and 17 in the ES), significantly fewer children in the SLCBT 
condition as compared to the ES condition experienced two or more flares post-treatment 
(16.7% versus 52.9%; p = .04).
DISCUSSION
This study was a large randomized controlled trial including a 1-year follow up period 
designed to test the efficacy of a brief cognitive behavioral intervention for children with 
IBD and their parents. The study evaluated treatment effects on process variables related to 
the intervention methods as well as outcome variables including quality of life, IBD 
symptoms, and school attendance. As predicted, results indicated that there was significantly 
more baseline to follow-up improvement in the SLCBT versus ES condition on process 
measures of parental solicitousness and parent-reported and child-reported child use of 
distract/ignore to cope with pain. Children's increased use of distract/ignore coping 
strategies was associated with significant increases, by parent-report, in children's beliefs in 
their pain coping efficacy. The observation by parents’ that children had increased 
confidence/belief in their problem-focused coping efficacy is consistent with the reports by 
both parents and children that the children increased their use of distraction/ignoring. It may 
thus be interpreted that they learned a strategy to cope with pain and this was associated with 
increased confidence in coping efficacy. Children in the SLCBT condition also reported 
greater improvement on the outcome measures of IBD-related quality of life overall 
compared to children in the ES group. Children in the SLCBT intervention missed 
significantly fewer school days for IBD and exploratory analyses indicated that for children 
with a higher level of flares (2 or more) pre-baseline, those in SLCBT experienced a greater 
reduction in flares post treatment compared to those in ES.
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The study did not find significant treatment effects for SLCBT compared to ES on child- or 
parent-reported depression or anxiety. Although depression and anxiety were not specific 
targets of intervention, higher prevalence of these psychological problems has been reported 
in children with IBD as noted in the introduction18,19 and it was of interest to determine if 
an intervention to improve stress management and coping might have secondary effects on 
psychosocial function. Children in both conditions reported significant improvement on 
psychosocial functioning and depression symptoms with no difference between groups. 
Lack of significant treatment effects in some outcome variables may be due to relatively low 
levels of active symptoms, restricting the range of possible improvement on those variables. 
It is also possible, given that prior CBT trials have shown that 12 sessions of CBT is 
efficacious in treating depression in youth with IBD,25 that our brief, 3-session intervention 
was insufficient to reduce depression and anxiety symptoms.
One limitation of the study was that our parent sample was comprised largely of mothers 
(90%). While in many cases mothers are the primary parent involved in a child's medical 
care, there is some evidence that fathers also play important roles in health behavior.59,60 
The efficacy of psychosocial treatments may be enhanced if both parents are included in 
treatment, but further research is needed to test this. Second, the study sample was primarily 
Caucasian, and thus the results may not generalize to minority children with IBD and their 
parents. Third, the majority of children with IBD in the study were described as in a 
quiescent state of disease symptomatology, which may have reduced the ability of this study 
to demonstrate significant effects of the intervention on some outcome variables. Another 
limitation was that given the nature of staffing of care providers in our recruitment sites, it 
was not possible to accurately track the number of patients who were originally made aware 
of the study. Finally, the psychometric properties of our method for determining flare counts 
were not determined. Findings on the reduction in number of flares in children with two or 
more flares pretreatment are intriguing, but require replication due to the small numbers of 
subjects in that subgroup, the limitations on the flare measure, and the exploratory nature of 
the analysis.
Nevertheless, this study demonstrated the efficacy of the SLCBT intervention in reducing 
school absences and improving quality of life, as well as increasing child use of distraction 
to cope with pain and reducing parental solicitousness. This intervention was relatively short 
(3 one-hour sessions) and therefore easily implemented in clinical practice. Although 
disability as measured by the FDI did not change significantly, it may be argued that 
improvement in functioning in important areas, such as school attendance and quality of life, 
are of at least equal if not greater importance to IBD management. Learning skills such as 
distraction and decreased catastrophizing may also have implications for continued self-
management and improved future outcomes. Helping parents to decrease solicitous 
behaviors and to encourage wellness and coping skill use may also have implications for 
facilitating self-management as children transition to self-care as young adults. Future 
research may consider intervening earlier post diagnosis to provide education and coping 
skills and allow earlier improvement at a time when families are beginning to process 
knowledge about the disease and its implications. Further studies may also consider focusing 
on children with greater symptomatology, increasing the number of sessions, intervening 
with more than one caregiver, or building in booster sessions to determine if this would 
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increase the magnitude of effects. Given the preliminary findings on flare reduction in more 
severely ill children, studies may consider focusing on this group as well. Investigations into 
factors that predict treatment response to facilitate targeting interventions would also be 
useful. Finally, consideration should be given to alternative delivery strategies, such as using 
an internet-based platform to deliver services to families who may not be able to access 
services in person.
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Figure 1. 
Study consort diagram
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Table 1
Baseline characteristics of the total sample and as a function of treatment condition.
All
N = 185
SLCBT
N = 91
ES
N = 94 P
1
Parent
Age, mean (SD), range 44.4 (6.9)
27 - 67
44.5 (6.6)
38 - 64
43.8 (7.1)
27 - 67 0.26
2
Gender, n (%) 0.06
    Male 18 (9.7) 5 (5.5) 13 (13.8)
    Female 167 (90.3) 86 (94.5) 81 (86.2)
Race, n (%) 0.914
    American Indian/ Alaska Native 1 (0.5) 1 (1.1) 0 (0)
    Asian 5 (2.7) 3 (3.3) 2 (2.1)
    Black or African American 4 (2.2) 2 (2.2) 2 (2.1)
    Native Hawaiian or other Pacific Islander 1 (0.5) 1 (1.1) 0 (0)
    Caucasian 161 (87.1) 79 (86.7) 82 (87.2)
    Mixed race 12 (6.5) 4 (4.4) 8 (8.5)
    Unknown 1 (0.5) 1 (1.1) 0 (0)
Ethnicity, n (%) 0.243
    Hispanic 3 (1.6) 0 (0) 3 (3.2)
    Not Hispanic 181 (97.9) 90 (98.9) 91 (96.8)
    Unknown 1 (0.5) 1 (1.1) 0 (0)
Educational status, n (%) 0.85
    High school degree or less 21 (11.4) 12 (13.2) 9 (9.6)
    Some college or technical school 73 (39.5) 34 (37.3) 39 (41.5)
    4-year college degree 42 (22.7) 20 (22.0) 22 (23.4)
    Some graduate/ professional school or post-baccalaureate degree 48 (25.9) 24 (26.4) 24 (25.5)
    Unknown 1 (0.5) 1 (1.1) 0 (0)
Marital status, n (%) 0.78
    Married/Cohabiting with partner 154 (83.3) 76 (83.5) 78 (83.0)
    Other situation 30 (16.2) 14 (15.4) 16 (17.0)
    Unknown 1 (0.5) 1 (1.1) 0 (0)
Employment, n (%) 0.47
    Full-time 81 (43.8) 36 (39.6) 45 (47.9)
    Part-time 47 (25.4) 26 (28.5) 21 (22.3)
    Not employed 55 (29.7) 28 (30.8) 27 (28.7)
    Unknown 2 (1.1) 1 (1.1) 1 (1.1)
Parent Crohn's or Ulcerative Colitis, n (%) 42 (22.7) 18 (19.8) 24 (25.5) 0.37
Child
Age, mean (SD), range 13.5 (2.7) 13.7 (2.5) 13.3 (2.9) 0.302
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All
N = 185
SLCBT
N = 91
ES
N = 94 P
1
8 - 17 8 - 17 8 - 17
Gender, n (%) 0.41
    Male 98 (53.0) 51 (56.0) 47 (50.0)
    Female 87 (47.0) 40 (44.0) 47 (50.0)
Ethnicity, n (%) 0.073
    Hispanic 8 (4.3) 1 (1.1) 7 (7.4)
    Not Hispanic 174 (94.1) 88 (96.7) 86 (91.5)
    Unknown 3 (1.6) 2 (2.2) 1 (1.1)
Race, n (%) 0.614
    American Indian/ Alaska Native 1 (0.5) 1 (1.1) 0 (0)
    Asian 5 (2.7) 3 (3.3) 2 (2.1)
    Black or African American 7 (3.8) 4 (4.4) 3 (3.2)
    Native Hawaiian or other Pacific Islander 3 (1.6) 2 (2.2) 1 (0.5)
    Caucasian 144 (77.9) 69 (75.8) 75 (79.8)
    Mixed race 24 (13.0) 11 (12.1) 13 (13.8)
    Unknown 1 (0.5) 1 (1.1) 0 (0)
Child IBS (Rome III diagnostic criteria-parent report), n (%) 5 (2.7) 3 (3.3) 2 (2.1) 0.683
Child IBS (Rome III diagnostic criteria-child report), n (%) 0 (0) 0 (0) 0 (0)
Physician-reported
Disease condition, n (%) 0.15
    Crohn's 127 (68.6) 67 (73.6) 60 (63.8)
    Ulcerative colitis 58 (31.4) 24 (26.4) 34 (36.2)
Disease severity, n (%) 0.40
    Quiescent 116 (63.0) 58 (63.7) 58 (62.4)
    Mild 53 (28.8) 28 (30.8) 25 (26.9)
    Moderate or severe 15 (8.2) 5 (5.5) 10 (10.8)
Location of ulcerative colitis 0.413
    Rectal (proctitis) 6 (11.5) 1 (4.3) 5 (17.2)
    Left-sided (colitis) 17 (32.7) 8 (34.8) 9 (31.0)
    Entire colon (pancolitis) 29 (55.8) 14 (60.9) 15 (51.7)
Location of Crohn's disease 0.69
    Small intestine only (ileitis) 30 (25.0) 16 (25.0) 14 (25.0)
    Small & large intestine (ileocolitis) 66 (55.0) 37 (57.8) 29 (51.8)
    Large intestine only (colitis) 24 (20.0) 11 (17.2) 13 (23.2)
Anal, rectal or vaginal problems, n (%) 15 (8.4) 9 (10.1) 6 (6.7) 0.41
Daily steroid medication, n (%) 41 (22.8) 18 (20.2) 23 (25.3) 0.42
Pain medication, n (%) 8 (4.3) 5 (5.5) 3 (3.2) 0.45
Medications for anxiety, n (%) 6 (3.3) 3 (3.3) 3 (3.2) 0.96
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All
N = 185
SLCBT
N = 91
ES
N = 94 P
1
Medications for depression, n (%) 10 (5.4) 5 (5.6) 5 (5.3) 0.94
Medications for hyperactivity, n (%) 5 (2.7) 3 (3.3) 2 (2.1) 0.62
1Chi-square test, p-value, unless noted otherwise
2
Two-sample t test
3
Fisher's exact test, p-value
4Caucasian vs. non-Caucasian
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Table 2
Baseline process and outcome variables as a function of treatment condition.
Process Variables All
N = 185
SLCBT
N = 91
ES
N = 94 P
1
Parent-report only, mean (SD)
ARCS: Protect (solicitousness) 0-4 scale 1.7 (0.7) 1.7 (0.6) 1.8 (0.7) 0.26
Parent and child-reported, mean (SD)
Parent-report
PRI: Child distract/ignore 0-4 scale 2.1(0.7) 2.1 (0.7) 2.1 (0.7) 0.66
    Child catastrophizing 0-4 scale 1.2(0.8) 1.2(0.8) 1.2(0.8) 0.75
PBQ: Threat of child pain 0-4 scale 2.2 (0.7) 2.3 (0.7) 2.2 (0.7) 0.51
    Child emotion-focused coping 0-4 scale 3.0 (0.7) 3.1 (0.7) 3.0 (0.7) 0.46
    Child problem-focused coping 0-4 scale 1.9 (0.8) 1.9 (0.8) 2.0 (0.8) 0.27
Child-report
PRI: Child catastrophizing 0-4 scale 1.0 (0.8) 1.0 (0.8) 1.0 (0.8) 0.57
    Child distract/ignore 0-4 scale 2.3 (0.8) 2.3 (0.9) 2.3 (0.7) 0.96
PBQ: Child perceived pain threat 0-4 scale 1.7 (0.8) 1.7 (0.8) 1.7 (0.8) 0.66
    Child emotion-focused coping 0-4 scale 3.0 (0.7) 3.1 (0.7) 3.0 (0.8) 0.13
    Child problem-focused coping 0-4 scale 2.3 (0.9) 2.4 (0.9) 2.3 (0.9) 0.50
Outcome Variables
Parent-report only, mean (SD)
Hospital stays in past 12 months 0.8 (1.4) 0.7 (1.1) 0.8 (1.6) 0.35
Health care visits for Crohn's or UC in past 12 months 9.3 (11.3) 7.1 (5.8) 11.5 (14.6) 0.01
Missed school days for Crohn's or UC in past 3 months 4.8 (9.4) 5.0 (9.5) 4.7 (9.3) 0.82
Child-report only, mean (SD)
IMPACT: Child IBD-specific quality of life; total score 33-175 scale 130.3 (19.2) 131.2 (16.9) 129.4 (21.4) 0.54
CDI: Child depression 0-54 scale 8.2 (7.4) 7.6 (7.1) 8.8 (7.6) 0.28
MASC: Child anxiety 0-30 scale 8.4 (2.9) 8.2 (2.8) 8.6 (2.9) 0.35
Parent and Child Reported, mean (SD)
Parent-report
FDI: Child functional disability 0-60 scale 6.7 (9.1) 6.8 (9.3) 6.6 (6.9) 0.88
Child-report
FDI: Child functional disability 0-60 scale 6.5 (7.1) 5.6 (5.7) 7.3 (8.2) 0.11
1
Two-sample t-test, p-value
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Table 3
Adjusted mean changes from baseline for process variables.1
Variable Change from baseline
1 week Mean 
(95% CI)
3 months Mean 
(95% CI)
6 months Mean 
(95% CI)
12 months P-value3
Mean (95% CI) Cohen's d2
Parent-reported
ARCS: Protect 
(solicitousness) 0-4 scale
    SLCBT
−0.4 (−0.6, −0.3)* −0.4 (−0,5, −0.2)* −0.4 (−0.5, −0.3)* −0.4 (−0.6, −0.3)* −0.76 <.001
    ES
−0.2 (−0.3, −0.0)* −0.3 (−0.4, −0.1)* −0.3 (−0.4, −0.1)* −0.2 (−0.4, −0.1)* −0.40 0.003
    Difference
−0.2 (−0.4, −0.1)* −0.1 (−0.3, 0.1) −0.1 (−0.3, 0.0) −0.2 (−0.4, −0.1) −0.36 0.02
Parent and Child-reported
Parent-report
PRI: Child distract/ignore 
0-4 scale
    SLCBT 0.3 (0.1, 0.4)* 0.2 (−0.0, 0.3) 0.2 (0.0, 0.4) 0.1 (−0.1, 0.2) 0.06 0.001
    ES −0.0 (−0.2, 0.1) −0.1 (−0.3, 0.1) −0.0 (−0.2, 0.1) 0.0 (−0.1, 0.2) 0.05 0.47
    Difference 0.4 (0.1, 0.5)* 0.3 (0.0, 0.5)* 0.2 (0.0, 0.4) 0.0 (−0.2, 0.2) 0.02 0.002
PRI: Child catastrophizing 
0-4 scale
    SLCBT
−0.3 (−0.4, −0.1)* −0.2 (−0.4, −0.1)* −0.2 (−0.4, −0.1)* −0.3 (−0.4, −0.1)* −0.27 0.009
    ES −0.0 (−0.2, 0.1) −0.1 (−0.2, 0.1) −0.2 (0.3, −0.0) −0.1 (−0.3, 0.0) −0.13 0.07
    Difference
−0.2 (−0.4, −0.1)* −0.2 (−0.3, 0.02) −0.1 (−0.2, 0.1) −0.2 (−0.4, 0.1) −0.14 0.12
PBQ: Threat of child pain 
0-4 scale
    SLCBT
−0.2 (−0.3, −0.1)* −0.1 (−0.3, 0.0) −0.2 (−0.3, −0.0)* −0.2 (−0.4, −0.1)* −0.36 0.03
    ES −0.0 (−0.1, 0.1) −0.1 (−0.3, 0.0) −0.1 (−0.3, 0.0) −0.1 (−0.3, 0.0) −0.23 0.28
    Difference −0.2 (−0.3, −0.0) −0.0 (−0.2, 0.1) −0.0 (−0.2, 0.1) −0.1 (−0.3, 0.1) −0.13 0.18
PBQ: Child emotion-
focused coping 0-4 scale
    SLCBT 0.3 (0.1, 0.4)* 0.3 (0.1, 0.4)* 0.3 (0.2, 0.4)* 0.4 (0.2, 0.5)* 0.54 <.001
    ES 0.2 (0.1, 0.3)* 0.2 (0.1, 0.3)* 0.1 (0.0, 0.3)* 0.2 (0.1, 0.4)* 0.34 0.001
    Difference 0.0 (−0.1, 0.2) 0.1 (−0.1, 0.2) 0.1 (−0.0, 0.3) 0.1 (−0.0, 0.3) 0.20 0.35
PBQ: Child problem-
focused coping 0-4 scale
    SLCBT 0.5 (0.3, 0.7)* 0.5 (0.3, 0.6)* 0.4 (0.2, 0.5)* 0.4 (0.2, 0.5)* 0.48 <.001
    ES 0.0 (−0.1, 0.2) 0.2 (−0.0, 0.3) 0.1 (−0.1, 0.2) 0.0 (−0.2, 0.2) 0.03 0.13
    Difference 0.5 (0.3, 0.6)* 0.3 (0.1, 0.5)* 0.3 (0.1, 0.5)* 0.3 (0.1, 0.6)* 0.44 <.001
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Variable Change from baseline
1 week Mean 
(95% CI)
3 months Mean 
(95% CI)
6 months Mean 
(95% CI)
12 months P-value3
Mean (95% CI) Cohen's d2
Child-report
PRI: Child distract/ignore 
0-4 scale
    SLCBT 0.3 (0.1, 0.5)* 0.3 (0.1, 0.5)* 0.1 (−0.1, 0.3) 0.1 (−0.1, 0.4) 0.14 0.03
    ES −0.0 (−0.2, 0.2) 0.0 (−0.2, 0.3) 0.1 (−0.1, 0.3) −0.0 (−0.3, 0.2) −0.02 0.49
    Difference 0.3 (0.0, 0.5) 0.3 (−0.0, 0.5) −0.0 (−0.3, 0.2) 0.2 (−0.1, 0.5) 0.16 0.04
PRI: Child catastrophizing 
0-4 scale
    SLCBT −0.1 (−0.3, 0.0) −0.2 (−0.3, 0.0) −0.1 (−0.3, 0.1)
−0.3 (−0.5, −0.1)* −0.42 0.01
    ES −0.0 (−0.2, 0.1) 0.1 (−0.1, 0.3) −0.0 (−0.2, 0.1) 0.0 (−0.2, 0.2) 0.03 0.64
    Difference −0.1 (−0.3, 0.1) −0.2 (−0.4, −0.0) −0.1 (−0.3, 0.2)
−0.3 (−0.5, −0.1)* −0.44 0.01
PBQ: Child perceived pain 
threat 0-4 scale
    SLCBT −0.1 (−0.2, 0.1) −0.1 (−0.3, 0.0) −0.0 (−0.2, 0.1) −0.1 (−0.2, 0.1) −0.11 0.13
    ES 0.1 (−0.0, 0.2) 0.0 (−0.2, 0.2) 0.0 (−0.2, 0.2) 0.1 (−0.1, 0.2) 0.08 0.47
    Difference −0.2 (−0.3, −0.0) −0.2 (−0.3, 0.0) −0.0 (−0.2, 0.1) −0.1 (−0.3, 0.1) −0.19 0.07
PBQ: Child emotion-
focused coping 0-4 scale
    SLCBT 0.2 (0.1, 0.4)* 0.2 (0.1, 0.4)* 0.1 (−0.0, 0.3) 0.2 (−0.0, 0.3) 0.24 0.03
    ES 0.1 (−0.1, 0.3) 0.1 (−0.1, 0.3) 0.1 (0.0, 0.3) 0.2 (0.0, 0.3) 0.24 0.30
    Difference 0.1 (−0.0, 0.3) 0.1 (−0.1, 0.3) −0.0 (−0.2, 0.1) 0.0 (−0.2, 0.2) 0.00 0.38
PBQ: Child problem-
focused coping 0-4 scale
    SLCBT 0.4 (0.2, 0.5)* 0.4 (0.2, 0.6)* 0.2 (−0.0, 0.4) 0.1 (−0.1, 0.4) 0.16 <.001
    ES 0.3 (0.1, 0.4)* 0.2 (−0.0, 0.4) 0.3 (0.1, 0.4)* 0.2 (0.0, 0.4) 0.24 0.03
    Difference 0.1 (−0.1, 0.3) 0.2 (−0.0, 0.4) −0.1 (−0.3, 0.1) −0.1 (−0.3, 0.2) 0.08 0.05
1
Estimated mean change from baseline based on linear mixed-effects regression model, adjusted for child gender, child age, disease condition and 
severity, study site and baseline level of the process variable.
2Cohen's d effect sizes based on the change between 12 months post-treatment and baseline; interpreted as: small (0.20), medium (0.50), or large 
(0.80).
3Omnibus test (df = 3) to evaluate overall change from baseline for all post-treatment periods (SLCBT or ES), and omnibus test (df = 3) to evaluate 
overall effect of intervention (Difference).
*
Bonferroni-Holm post-hoc test for change from baseline for SLCBT or ES, and for SLCBT/ES treatment difference (p < 0.05)
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Table 4
Adjusted mean changes from baseline for outcome variables.1
Variable Change from baseline
1 week Mean 
(95% CI)
3 months Mean 
(95% CI)
6 months Mean 
(95% CI)
12 months P-value3
Mean (95% CI) Cohen's d2
Child-Reported
IMPACT: Child IBD-
specific quality of life 
35-175 scale
    SLCBT 6.3 (3.1, 9.6)* 5.9 (2.4, 9.4)* 4.9 (1.0, 8.9)* 5.5 (1.6, 9.5)* 0.37 0.003
    ES 2.1 (−1.2, 5.3) 3.2 (−0.5, 6.8) 5.3 (1.3, 9.3)* 5.6 (1.6, 9.6)* 0.37 0.04
    Difference 4.3 (1.0, 7.5)* 2.7 (−1.4, 6.8) −0.4 (−4.3, 3.6) −0.1 (−4.4, 4.3) 0.00 0.04
CDI: Child depression 0-54 
scale
    SLCBT
−3.2 (−4.3, −2.1)* −3.8 (−5.0, −2.7)* −2.3 (−3.5, −1.1)* −3.0 (−4.2, −1.7)* −0.52 <.001
    ES
−3.1 (−4.1, −2.0)* −3.2 (−4.4, −2.1)* −3.2 (−4.2, −2.1)* −3.6 (−4.9, −2.3)* −0.63 <.001
    Difference 0.1 (−1.3, 1.0) −0.6 (−1.9, 0.7) 0.8 (−0.5, 2.2) 0.6 (−0.9, 2.1) 0.11 0.10
MASC: Child anxiety 0-30 
scale
    SLCBT −0.2 (−0.9, 0.5) −0.4 (−1.2, 0.4) −0.6 (−1.3, 0.2) −0.6 (−1.5, 0.3) −0.21 0.53
    ES −0.2 (−0.8, 0.5) −0.3 (−1.0, 0.4) −0.4 (−1.2, 0.3) −0.8 (−1.7, 0.1) −0.26 0.37
    Difference −0.0 (−0.7, 0.6) −0.1 (−0.9, 0.8) −0.2 (−1.0, 0.7) 0.2 (−0.9, 1.2) 0.05 0.97
Parent and Child-reported
Parent-Report
FDI: Child functional 
disability 0-60 scale
    SLCBT −0.1 (−2.5, 2.3) −1.7 (−3.8, 0.3) −1.6 (−3.8, 0.6) −1.3 (−3.5, 1.0) −0.12 0.41
    ES −0.3 (2.5, 1.9) −1.0 (−2.9, 0.8) −0.2 (−2.3, 1.9) −0.4 (−2.8, 2.0) −0.04 0.82
    Difference 0.2 (−2.6, 3.0) −0.7 (−3.0, 1.7) −1.4 (−4.0, 1.2) −0.9 (−3.6, 1.9) −0.08 0.86
Child-report
FDI: Child functional 
disability 0-60 scale
    SLCBT 0.1 (−1.3, 1.5) 0.3 (−1.3, 1.9) 0.3 (−1.5, 2.0) 0.2 (−1.5, 2.0) 0.02 0.99
    ES 0.0 (−1.4, 1.3) 0.1 (−1.6, 1.7) 0.2 (−1.4, 1.7) 0.1 (−1.6, 1.8) 0.01 0.99
    Difference 0.1 (−1.2, 1.5) 0.2 (−1.5, 2.0) 0.1 (−1.8, 2.0) 0.1 (−2.0, 2.2) 0.01 0.99
4
 To calculate the change from baseline at post-treatment for the number of health care visits in the past 3 months, baseline numbers were divided 
by four as an estimate of the number of health care visits in the 3 months prior to baseline.
1
Estimated mean change from baseline based on linear mixed-effects regression model, adjusted for child gender, child age, disease condition and 
severity, study site and baseline level of the outcome.
2Cohen's d effect sizes based on the change between 12 months post-treatment and baseline; designated as small (0.20), medium (0.50), or large 
(0.80).
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3Omnibus test (df = 3) to evaluate overall change from baseline for all post-treatment periods (SLCBT or ES), and omnibus test (df = 3) to evaluate 
overall effect of intervention (Difference).
*
Bonferroni-Holm post-hoc test for change from baseline for SLCBT or ES, and for treatment difference, SLCBT – ES (p < 0.05)
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Table 5
Adjusted rate ratios for number of health care visits and number of missed school days for Crohn's or 
ulcerative colitis.1
Variable 3 months RR (95% 
CI)
6 months RR (95% CI) 12 months RR (95% 
CI) P-value
2
Number of child health care 
visits, past 3 months
SLCBT vs ES 1.11 (0.73, 1.66) 0.74 (0.50, 1.06) 0.82 (0.56, 1.19) 0.16
Number of missed school 
days, past 3 months
SLCBT vs ES 0.98 (0.54, 1.75) 0.43 (0.22, 0.80)* 0.62 (0.34, 1.13) 0.02
1
Estimated rate ratio based on GEE log-linear regression model, adjusted for child gender, child age, disease condition and severity, study site and 
number of health care visits (12 months prior to baseline) or number of missed school days (3 months prior to baseline).
2Omnibus test (df = 3) to evaluate overall effect of intervention (difference).
*
Bonferroni-Holm post-hoc test for treatment difference (p < 0.05)
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